AIF1 and melanoma: Moreover, dual immunofluorescence analysis of microglial expression of a DAMP response marker, TLR4, showed elevated TLR4-IBA1 immunoreactivity (29–60% increase) in the melanoma + vehicle and combi-ICI-treated groups (Fig. 4D-E).